Bristol Myers Squibb (BMY) Divestments (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Divestments data on file, last reported at $312.0 million in Q1 2026.

• Quarterly Divestments rose 28.4% year-over-year to $312.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 3.54% YoY) and the FY2025 annual result came in at $1.1 billion, down 2.55% from the prior year.
• Divestments improved to $312.0 million in Q1 2026 per BMY's latest filing, from $279.0 million in the prior quarter.
• Across five years, Divestments topped out at $490.0 million in Q4 2022 and bottomed at $192.0 million in Q2 2022.
• The 5-year median for Divestments is $255.0 million (2024), against an average of $276.2 million.
• The widest annual swing landed in 2022, when Divestments jumped 175.28%; it then slumped 50.82% in 2023.
• Tracing BMY's Divestments over 5 years: stood at $490.0 million in 2022, then tumbled by 50.82% to $241.0 million in 2023, then surged by 38.17% to $333.0 million in 2024, then decreased by 16.22% to $279.0 million in 2025, then advanced by 11.83% to $312.0 million in 2026.
• Per Business Quant, the three latest BMY Divestments figures stand at $312.0 million (Q1 2026), $279.0 million (Q4 2025), and $279.0 million (Q3 2025).

Peer Comparison